The best-performing unit trusts have exposure to US tech stocks, while the laggards were invested in commodities and ...

Browse in-depth TOC on " Global Biotechnology industry Outlook " 10 - Tables 20 - Figures 70 - Pages . The Global Biotech ...

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

British fund manager Terry Smith has sold his stake in Diageo Plc, citing concerns about the management of the drinks company and its vulnerability to soaring demand for weight-loss drugs.

Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $85.64 which represents a slight increase of $2.30 or 2.76% from the prior close of $83.34. The stock opened at $85.51 and touched a ...

The company plans to create a new category of cellular medicines offering functional cures for metabolic and endocrine ...

President-elect Donald Trump threatened Tuesday to place new tariffs on imports from Denmark unless the country gives up control of Greenland, news that dented the stocks of some of Denmark's most ...

Brown-Forman's stock is a compelling investment with stable revenue and profit margins. Learn why BF.B is a Buy.

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...